Trial Profile
A population pharmacokinetic trial to study patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Dec 2015
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Pharmacokinetics
- 09 Dec 2015 New trial record